Literature DB >> 1717543

Is autoimmune chronic active hepatitis a HCV-related disease?

S Magrin1, A Craxì, G Fiorentino, C Fabiano, G Provenzano, G B Pinzello, U Palazzo, P Almasio, L Pagliaro.   

Abstract

We evaluated the specificity and clinical relevance of anti-hepatitis C virus antibody positivity in 22 HBsAg-negative patients with autoimmune (anti-nuclear, anti-actin or anti-liver-kidney microsomal antibody positive) chronic active hepatitis. An ELISA anti-HCV test and a recombinant immunoblot assay (RIBA-HCV) were used. Thirteen patients (59%) were anti-HCV positive and five (23%) anti-HCV negative by both ELISA and RIBA-HCV tests. Four patients (18%) were borderline positive by ELISA (OD less than 1.0), and three of them (all with severe disease) were negative by RIBA. Histologic necroinflammation, AST/ALT and gamma-globulins levels were higher and response to prednisolone treatment was better in RIBA anti-HCV-negative than in anti-HCV-positive cases. We confirmed with both RIBA and ELISA tests the high prevalence of anti-HCV already reported by ELISA in anti-nuclear and anti-liver-kidney microsomal antibody positive chronic active hepatitis. False positive for anti-HCV (i.e., a positive ELISA test not confirmed by RIBA) occurred only among patients with severe disease. Since RIBA-negative subjects showed the best response to corticosteroid, they might represent the only subset of cases of 'true' autoimmune chronic active hepatitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717543     DOI: 10.1016/0168-8278(91)90864-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

Review 1.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 2.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

Review 3.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 4.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

5.  Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection.

Authors:  Y Ma; M Peakman; A Lobo-Yeo; L Wen; M Lenzi; J Gäken; F Farzaneh; G Mieli-Vergani; F B Bianchi; D Vergani
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact?

Authors:  B P Rowan; A Smith; D Gleeson; L P Hunt; T W Warnes
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

7.  Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection.

Authors:  F Cassani; L Muratori; P Manotti; M Lenzi; M Fusconi; G Ballardini; L Selleri; U Volta; D Zauli; R Miniero
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

8.  Immune response to GOR, a marker for non-A, non-B hepatitis and its correlation with hepatitis C virus infection.

Authors:  S U Mehta; S Mishiro; K Sekiguchi; T Leung; G J Dawson; L M Pendy; D A Peterson; S G Devare
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

9.  Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA.

Authors:  R Seelig; M Renz; G Bünger; H Schröter; H P Seelig
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

Review 10.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.